CERo Therapeutics Announces Trading on OTCQB Market
Aggressive cancer warning signs revealed after JFK's granddaughter's diagnosis [FOX News]
CERo Therapeutics (NASDAQ:CERO) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
CERo Therapeutics (NASDAQ:CERO) had its "hold" rating reaffirmed by analysts at D. Boral Capital.
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing